aTyr Pharma, Inc. (NASDAQ:ATYR) is a favorite amongst institutional investors who own 57% [Yahoo! Finance]
aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors
Atyr PHARMA INC (NASDAQ: ATYR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
aTyr Pharma Announces Third Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis [Yahoo! Finance]